Simrat Randhawa bought DNTH once, on Sep 21, 2023
EVP, Head of R&D at Dianthus Therapeutics, Inc.
SEC CIK 0001992260 · Filings on SEC.gov ↗
Simrat Randhawa's record
3 months after each buy, from the first price a copier could get.
1 buy has 3 months of prices so far. A record shows here at 3.
Every filing
4 filings since Sep 2023, newest first
About Simrat Randhawa
Simrat Randhawa is an Executive Vice President and Head of Research and Development at Dianthus Therapeutics, Inc., a clinical-stage biotechnology company headquartered in New York( She holds an M.D. from Drexel University and an M.B.A.( and has served as an executive officer at Dianthus since 2022( In her leadership role, Randhawa oversees the research and development operations for the company's pipeline of complement therapeutics designed to treat severe autoimmune and inflammatory diseases(
Randhawa has been actively involved in insider transactions at Dianthus Therapeutics, recently exercising stock options for 33,830 shares and selling the same number of shares at $81.48 per share on March 12, 2026, for a total transaction value of approximately $2.76 million( The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 14, 2025( and following the transaction, she held no direct common stock holdings in the company(
Written by Perplexity from public sources.
Filings come from SEC EDGAR. Not investment advice.